Navigation Links
Nabriva Therapeutics Announces Appointment of New CEO
Date:7/2/2008

VIENNA, Austria, July 3 /PRNewswire/ -- Nabriva Therapeutics, a specialist in antibiotics development, announces that Dr. George Golumbeski has been appointed as Chief Executive Officer of the Company.

Dr. Golumbeski brings to the team nearly twenty years of industry experience serving most recently as Vice President of Business Development, Licensing & Strategy for the oncology business unit at Novartis. In this position he was responsible for the full array of business development activities leading several transactions which have resulted in projects currently in Phase III studies. While at Novartis, Dr. Golumbeski also served as a member of the Executive Committee which oversees overall oncology business performance. Prior to his tenure at Novartis, he led transactions which have resulted in two products that have been approved or are in registration in the US and the EU.

"I am excited to join Nabriva at this important stage of its growth. The Company's highly differentiated compounds have the potential to address the significant need for new classes of effective antibiotics. Furthermore, the team at Nabriva is highly experienced with a deep understanding and enthusiasm for the development of novel antibiotics," commented Dr. Golumbeski.

David Chiswell, Chair of the Supervisory Board, added, "We are pleased to welcome George to the team. His leadership skills combined with his strategic and business development insight will help position Nabriva as one of the leading specialist companies in antibiotics development."

About Nabriva Therapeutics:

Headquartered in Vienna, Nabriva Therapeutics is engaged in the discovery and development of innovative antibacterial agents addressing unmet medical need in the hospital and community setting. The company has two compounds currently in clinical trials and expects to have a third compound enter clinical trials later this year. The lead compound, BC-3205, is a parenterally and orall
'/>"/>

SOURCE Nabriva Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Pearl Therapeutics Closes $18 Million Financing Round Led By Committed Investors
2. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
3. Joseph B. Bolen, Ph.D. from Millennium to Conference Chair Cancer Sessions at IBCs Drug Discovery & Development of Innovative Therapeutics Conference
4. Tobira Therapeutics Inc. Announces Senior Management Team
5. Duska Therapeutics Obtains Standard & Poors Listing
6. Spectral announces continuing support for the combination of EAA(TM) and anti-endotoxin therapeutics
7. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
8. Sirion Therapeutics Announces FDA Approval of Durezol(TM) for Treatment of Postoperative Ocular Inflammation and Pain
9. Commercial Launch of Lexiscan(TM) (Regadenoson) Injection Triggers $10 Million Milestone Payment from TPG-Axon Capital to CV Therapeutics
10. Barrier Therapeutics to Merge Into Stiefel Laboratories
11. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... used for detailed studies of what happens on the ... research, among other applications. A group of researchers from ... cell membranes form across a large number of vertical ... the interior of a cell and its surroundings takes ... surface layer that holds the cell together and that ...
(Date:9/2/2014)... 2, 2014  TransCelerate BioPharma Inc. ("TransCelerate") today ... for protecting personal data in Clinical Study Reports ... others. The document describes an approach to apply ... and other related clinical trial documents, and is ... of the TransCelerate CSR Redaction approach is to ...
(Date:9/2/2014)... 2014 Orexigen Therapeutics, Inc. (Nasdaq: ... Trademark Office (PTO) has issued a patent related to ... loss. NB32 is a fixed-dose combination of naltrexone sustained ... No. 8,815,889 claims methods for treating insulin resistance using ... in 2024. If NB32 is approved for use in ...
(Date:9/2/2014)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... three large odour control systems for waste water treatment plants ... are consistent with the market resurgence in North ... CEO. "After a difficult period of restraint in our core ... sales growth. Our lower cost structure, technology improvements and supply ...
Breaking Biology Technology:Nano-forests to reveal secrets of cells 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4
... 13 /PRNewswire-Asia/ -- IVT Corporation announced today that,it will demonstrate ... Hong Kong on Nov. 18-19, at Booth F08, and CES ... reducing risk of diseases and,assisting with emergency rescue. , ... It includes: , 1) ...
... Nov. 12 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq:,SSRX) ("3SBio" or ... developing, manufacturing and marketing,biopharmaceutical products, today announced its unaudited ... , , Third Quarter 2009 Financial ... by 35.8% over the third quarter of 2008 to, ...
... AvidBiotics Corp. announced the issuance of foundational ... massive diversity within precisely targeted sites of protein-encoding ... to as Diversity Generating Retroelements (DGR) and patents ... and in Europe (#1,173,995). UCLA and AvidBiotics ...
Cached Biology Technology:IVT will Demo Mobile Health System at GSMA Mobile Asia Congress and CES 2010 23SBio Inc. Announces Unaudited Third Quarter 2009 Results 23SBio Inc. Announces Unaudited Third Quarter 2009 Results 33SBio Inc. Announces Unaudited Third Quarter 2009 Results 43SBio Inc. Announces Unaudited Third Quarter 2009 Results 53SBio Inc. Announces Unaudited Third Quarter 2009 Results 63SBio Inc. Announces Unaudited Third Quarter 2009 Results 73SBio Inc. Announces Unaudited Third Quarter 2009 Results 83SBio Inc. Announces Unaudited Third Quarter 2009 Results 93SBio Inc. Announces Unaudited Third Quarter 2009 Results 103SBio Inc. Announces Unaudited Third Quarter 2009 Results 113SBio Inc. Announces Unaudited Third Quarter 2009 Results 123SBio Inc. Announces Unaudited Third Quarter 2009 Results 133SBio Inc. Announces Unaudited Third Quarter 2009 Results 143SBio Inc. Announces Unaudited Third Quarter 2009 Results 153SBio Inc. Announces Unaudited Third Quarter 2009 Results 163SBio Inc. Announces Unaudited Third Quarter 2009 Results 173SBio Inc. Announces Unaudited Third Quarter 2009 Results 183SBio Inc. Announces Unaudited Third Quarter 2009 Results 193SBio Inc. Announces Unaudited Third Quarter 2009 Results 203SBio Inc. Announces Unaudited Third Quarter 2009 Results 21AvidBiotics Corp. Granted Key U.S. and European Patents on Unique Protein Modification Platform 2
(Date:9/2/2014)... history of scientific research on mountain ecosystems, looks ... and sets an agenda for biodiversity conservation throughout ... gloom and mountain glory revisited: A survey of ... appears online in the Journal of Mountain ... Tufts University, Jodi A. Hilty of the Wildlife ...
(Date:9/2/2014)... always true that digital distribution of media will ... means, at least when file sizes are large. ... in Yale,s Journal of Industrial Ecology ... for consoles such as PlayStation3. Researchers found that ... greenhouse gas emissions than game files downloaded over ...
(Date:9/2/2014)... R.I. [Brown University] It,s hard to comprehend how ... world has become without knowing what it was before ... pre-human rate was 10 times lower than scientists had ... times worse. , Extinctions are about 1,000 times more ... people came along. The explanation from lead author Jurriaan ...
Breaking Biology News(10 mins):An uphill climb for mountain species? 2An uphill climb for mountain species? 3Extinctions during human era worse than thought 2Extinctions during human era worse than thought 3
... A University of Utah biologist and an international research team ... hope for new ways to attack the major pest, which ... The voracious mites, which technically are not insects, can ... The mites, newly revealed and sequenced genome contains a variety ...
... of Illinois at Chicago College of Medicine describe for ... checkpoint enzymes that must be chemically modified to enable ... thought to play a key role in cancer and ... Nature Structural and Molecular Biology . Telomeres are ...
... recent opening of its new Biomolecular Labeling Laboratory, the ... one of a small handful of facilities in the ... isotopes to make them easier to analyze. The new ... in biomedical fields who also want to take advantage ...
Cached Biology News:Big pest, small genome 2Big pest, small genome 3Big pest, small genome 4UIC study identifies a key molecular switch for telomere extension by telomerase 2Tags? We're it. NIST opens new 'biolabeling' research facility 2
... is a very sensitive immunohistochemical tool for ... both anti-von Willebrand Factor and anti-CD31 primary ... of species. This AP kit provides a ... frozen and paraffin-embedded sections in human (both ...
... Applied Biosystems and MDS Sciex ... System, a high performance hybrid triple ... the drug discovery, drug development or ... (LIT) Technology from the leaders in ...
... 18 amino acid synthetic peptide whose sequence corresponds to residues 1-18 ... (amino to carboxy terminus): M(1) - A - S - A ... S - P - R - D - A - A ... be used for neutralization and control experiments with the polyclonal antibody ...
... is a fixative useful for routine procedures. ... is stable and will decalcify small bone ... can be stained successfully with most stains, ... stabilizes red blood cell membranes and cosinophil ...
Biology Products: